<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242020000402020</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Implicaciones de la microbiota intestinal en las enfermedades crónicas del hígado]]></article-title>
<article-title xml:lang="en"><![CDATA[Implications of the intestinal microbiota in the chronic liver diseases.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bruce]]></surname>
<given-names><![CDATA[Dr. Alfredo Arredondo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo Rubido]]></surname>
<given-names><![CDATA[Alfredo E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Provincial Docente Amalia Simoni  ]]></institution>
<addr-line><![CDATA[ Camagüey]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>42</volume>
<numero>4</numero>
<fpage>2020</fpage>
<lpage>2031</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242020000402020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242020000402020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242020000402020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La microbiota se refiere al conjunto de todos los de microorganismos que se localizan de manera normal en distintos sitios de los cuerpos de los seres vivos pluricelulares, tales como el cuerpo humano. Las modificaciones del eje intestino-hígado se ha convertido en la actualidad en un grave problema científico al haberse encontrado en diversas investigaciones, que esta microbiota está relacionada con el daño hepático con independencia de la causa de la lesión hepática. Se realizó una revisión sistemática sobre las implicaciones demamicrobiota intestinal en las enfermedades hepáticas. Se realizó una revisión de artículos científicos publicados entre 2012 y 2018 en diversas bases de datos en línea. Se presenta el conocimiento existente hasta el momento sobre la microbiota intestinal en pacientes portadores de enfermedades hepáticas, con hincapié en las hepatitis C y la cirrosis hepática. La composición de microbiota de intestino estuvo asociada con el perfil inflamatorio y marcadores de fibrosis hepática, las que mejoraron con el tratamiento de antivirales de acción directa aunque las medidas de permeabilidad intestinal e inflamación permanecían inalteradas. Se reporta mejoría de los pacientes portadores de hepatitis viral tipo C, con antivirales de acción directa la cual estuvo asociada con modificaciones de la microbiota intestinal, que se correlacionó con mejoría en la fibrosis e inflamación hepática, los avances en este campo abren nuevas perspectivas en la biomedicina.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Microbiota refers to the whole of microorganisms located in a normal way in different places of the bodies of pluricelular living beings, like the human body. The modifications of the axis intestine-liver have become a serious scientific problem, because in different researches researchers have found that this microbiota is related to hepatic damage depending on the cause of this hepatic lesion. To carry out a systematic review on the implication of intestinal macrobiota in liver diseases. The scientific articles published in the period 2012-2018 in different databases on line were reviewed. A total of 26 bibliographic sources were used, original articles and reviews. The authors present knowledge existent up to the moment on intestinal microbiota in patients who have liver diseases, making emphasis on hepatitis C and hepatic cirrhosis. The composition of the intestine microbiota was associated to an inflammatory and markers of hepatic fibrosis that improved with the treatment of direct action antivirals although the measures of intestinal permeability and inflammation remained inalterably. It is reported an improvement of patients carriers of viral hepatitis type C with the use direct action retrovirals, what was linked to modifications in the intestinal microbiota, and correlated to an improvement of fibrosis and liver inflammation; the advances obtained in this field open new perspectives in biomedicine.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[microbiota]]></kwd>
<kwd lng="es"><![CDATA[cirrosis hepática]]></kwd>
<kwd lng="es"><![CDATA[virus hepatitis C]]></kwd>
<kwd lng="es"><![CDATA[respuesta virológica sostenida]]></kwd>
<kwd lng="es"><![CDATA[antivirales directos]]></kwd>
<kwd lng="es"><![CDATA[interferón]]></kwd>
<kwd lng="en"><![CDATA[microbiota]]></kwd>
<kwd lng="en"><![CDATA[hepatic cirrhosis]]></kwd>
<kwd lng="en"><![CDATA[hepatitis C virus]]></kwd>
<kwd lng="en"><![CDATA[sustained virological answer]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Añé Kourí]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El viroma humano. Implicaciones en la salud y enfermedad]]></article-title>
<source><![CDATA[Rev Haban Cienc Méd]]></source>
<year>2018</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>376-85</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ariza-Andraca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García-Ronquillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El microbioma humano. Su papel en la salud y en algunas enfermedades]]></article-title>
<source><![CDATA[Rev Cirug y Ciruj]]></source>
<year>2016</year>
<volume>84</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral Microbiota and Liver Disease]]></article-title>
<source><![CDATA[The Human Gut-Liver-Axis in Health and Disease]]></source>
<year>2019</year>
<page-range>105-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garges]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Giovanni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The NIH Human Microbiome Project]]></article-title>
<source><![CDATA[Genome Resec]]></source>
<year>2009</year>
<volume>19</volume>
<page-range>2317-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almaguer Mederos]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Martínez]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Guach Hevia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implicaciones de la microbiota intestinal en la etiología y terapéutica de la enfermedad de Parkinson]]></article-title>
<source><![CDATA[Rev Haban Cienc Méd]]></source>
<year>2018</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-57</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations of the human gut microbiome in liver cirrhosis]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2014</year>
<volume>513</volume>
<numero>7516</numero>
<issue>7516</issue>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bajaj]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Heuman]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Hylemon]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Altered profile of human gut microbiome is associated with cirrhosis and its complications]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2014</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>940-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidrich]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vital]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Plumeier]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls]]></article-title>
<source><![CDATA[Liver Int]]></source>
<year>2018</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Scherzer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2018</year>
<volume>217</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1289-97</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aly]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Adel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[El-Gendy]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gut microbiome alterations in patients with stage 4 hepatitis C]]></article-title>
<source><![CDATA[Gut Pathog]]></source>
<year>2016</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakayama]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moriya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gut dysbiosis associated with hepatitis C virus infection]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2018</year>
<volume>67</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>869-77</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schloss]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dynamics and associations of microbial community types across the human body]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2014</year>
<volume>509</volume>
<numero>7500</numero>
<issue>7500</issue>
<page-range>357-60</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Highlights from Barcelona 2012 International Liver Congress and EASL meeting]]></article-title>
<source><![CDATA[Biotecnol]]></source>
<year>2013</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>145-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tedesco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thapa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chin C]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic &#947;&#948; T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2018</year>
<volume>154</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2178-93</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Brach]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease. The Human Gut-Liver-Axis in Health and Disease]]></source>
<year>2019</year>
<page-range>89-104</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manns]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Buti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gane]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C virus infection]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>17006</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gogela]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2018</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>486-92</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romana-Ponziani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Putignani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[ParoniSterbini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of Hepatitis C Virus Eradication With Direct-acting Antivirals on the Gut Microbiota in Patients with Cirrhosis]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2018</year>
<volume>48</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>1301- 11</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolmazashvili]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Abutidze]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chkhartishvili]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>29</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1223-30</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciocan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rebours]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Voican]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis]]></article-title>
<source><![CDATA[Scientific reports]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4822</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridlon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hylemon]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Bajaj]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut]]></article-title>
<source><![CDATA[Dig Dis]]></source>
<year>2015</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>338-45</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacchi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cima]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Corbella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2015</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-25</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bajaj]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Sterling]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Betrapally]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2016</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>638-43</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kared]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fabre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bedard]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C]]></article-title>
<source><![CDATA[PLoS Pathog]]></source>
<year>2013</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection]]></article-title>
<source><![CDATA[Cytokine]]></source>
<year>2012</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>138-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponziani]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Putignani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Paroni Sterbini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of hepatitis C virus eradication with direct&#8208;acting antivirals on the gut microbiota in patients with cirrhosis]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2018</year>
<volume>48</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>1301-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
